

# Ana Barac

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7150455/publications.pdf>

Version: 2024-02-01

133  
papers

8,852  
citations

70961

41  
h-index

45213

90  
g-index

135  
all docs

135  
docs citations

135  
times ranked

9018  
citing authors

#	ARTICLE	IF	CITATIONS
1	Expert Consensus for Multimodality Imaging Evaluation of Adult Patients during and after Cancer Therapy: A Report from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. <i>Journal of the American Society of Echocardiography</i> , 2014, 27, 911-939.	1.2	1,051
2	Prevention and Monitoring of Cardiac Dysfunction in Survivors of Adult Cancers: American Society of Clinical Oncology Clinical Practice Guideline. <i>Journal of Clinical Oncology</i> , 2017, 35, 893-911.	0.8	860
3	Expert consensus for multimodality imaging evaluation of adult patients during and after cancer therapy: a report from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. <i>European Heart Journal Cardiovascular Imaging</i> , 2014, 15, 1063-1093.	0.5	739
4	Management of cardiac disease in cancer patients throughout oncological treatment: ESMO consensus recommendations. <i>Annals of Oncology</i> , 2020, 31, 171-190.	0.6	582
5	Cardiovascular Disease and Breast Cancer: Where These Entities Intersect: A Scientific Statement From the American Heart Association. <i>Circulation</i> , 2018, 137, e30-e66.	1.6	500
6	Cardio-Oncology Rehabilitation to Manage Cardiovascular Outcomes in Cancer Patients and Survivors: A Scientific Statement From the American Heart Association. <i>Circulation</i> , 2019, 139, e997-e1012.	1.6	258
7	Class IV Semaphorins Promote Angiogenesis by Stimulating Rho-Initiated Pathways through Plexin-B. <i>Cancer Research</i> , 2004, 64, 5212-5224.	0.4	214
8	Defining cardiovascular toxicities of cancer therapies: an International Cardio-Oncology Society (IC-OS) consensus statement. <i>European Heart Journal</i> , 2022, 43, 280-299.	1.0	213
9	Cardiovascular magnetic resonance in immune checkpoint inhibitor-associated myocarditis. <i>European Heart Journal</i> , 2020, 41, 1733-1743.	1.0	212
10	Cardiovascular Health of Patients With Cancer and Cancer Survivors. <i>Journal of the American College of Cardiology</i> , 2015, 65, 2739-2746.	1.2	198
11	2012 American College of Cardiology Foundation/Society for Cardiovascular Angiography and Interventions Expert Consensus Document on Cardiac Catheterization Laboratory Standards Update. <i>Journal of the American College of Cardiology</i> , 2012, 59, 2221-2305.	1.2	191
12	Role of serum biomarkers in cancer patients receiving cardiotoxic cancer therapies: a position statement from the <scp>Cardio-Oncology Study Group</scp> of the <scp>Heart Failure Association</scp> and the <scp>Cardio-Oncology Council of the European Society of Cardiology</scp>. <i>European Journal of Heart Failure</i> , 2020, 22, 1966-1983.	2.9	184
13	Global Longitudinal Strain and Cardiac Events in Patients With Immune Checkpoint Inhibitor-Related Myocarditis. <i>Journal of the American College of Cardiology</i> , 2020, 75, 467-478.	1.2	179
14	Cardio-Oncology: Vascular and Metabolic Perspectives: A Scientific Statement From the American Heart Association. <i>Circulation</i> , 2019, 139, e579-e602.	1.6	142
15	Major Adverse Cardiovascular Events and the Timing and Dose of Corticosteroids in Immune Checkpoint Inhibitor-Associated Myocarditis. <i>Circulation</i> , 2020, 141, 2031-2034.	1.6	142
16	Ibrutinib-Associated Atrial Fibrillation. <i>JACC: Clinical Electrophysiology</i> , 2018, 4, 1491-1500.	1.3	134
17	Methods for Evaluating Endothelial Function in Humans. <i>Hypertension</i> , 2007, 49, 748-760.	1.3	116
18	Diabetes and incident heart failure in hypertensive and normotensive participants of the Strong Heart Study. <i>Journal of Hypertension</i> , 2010, 28, 353-360.	0.3	115

#	ARTICLE	IF	CITATIONS
19	Homo- and hetero-oligomerization of PDZ-RhoGEF, LARG and p115RhoGEF by their C-terminal region regulates their in vivo Rho GEF activity and transforming potential. <i>Oncogene</i> , 2004, 23, 233-240.	2.6	107
20	Prospective evaluation of the cardiac safety of HER2-targeted therapies in patients with HER2-positive breast cancer and compromised heart function: the SAFE-HEaRt study. <i>Breast Cancer Research and Treatment</i> , 2019, 175, 595-603.	1.1	106
21	G Protein-Coupled Receptor-Mediated Mitogen-Activated Protein Kinase Activation through Cooperation of G $\beta$ q and G $\beta$ i Signals. <i>Molecular and Cellular Biology</i> , 2000, 20, 6837-6848.	1.1	101
22	Myocardial T1 and T2 Mapping by Magnetic Resonance in Patients With Immune Checkpoint Inhibitor-Associated Myocarditis. <i>Journal of the American College of Cardiology</i> , 2021, 77, 1503-1516.	1.2	97
23	The small GTPase Rac1 links the Kaposi sarcoma-associated herpesvirus vGPCR to cytokine secretion and paracrine neoplasia. <i>Blood</i> , 2004, 104, 2903-2911.	0.6	95
24	Dietary Modification and Breast Cancer Mortality: Long-Term Follow-Up of the Women's Health Initiative Randomized Trial. <i>Journal of Clinical Oncology</i> , 2020, 38, 1419-1428.	0.8	87
25	Sex differences in obesity-related changes in left ventricular morphology: the Strong Heart Study. <i>Journal of Hypertension</i> , 2011, 29, 1431-1438.	0.3	80
26	Chimeric Antigen Receptor T-Cell Therapy for Cancer and Heart. <i>Journal of the American College of Cardiology</i> , 2019, 74, 3153-3163.	1.2	78
27	Cardiovascular Complications Associated With Novel Cancer Immunotherapies. <i>Current Treatment Options in Cardiovascular Medicine</i> , 2017, 19, 36.	0.4	75
28	Cardiovascular Disease After Aromatase Inhibitor Use. <i>JAMA Oncology</i> , 2016, 2, 1590.	3.4	74
29	Autoimmune Myocarditis Caused by Immune Checkpoint Inhibitors Treated With Antithymocyte Globulin. <i>Journal of Immunotherapy</i> , 2018, 41, 332-335.	1.2	68
30	ACC 2015 Core Cardiovascular Training Statement (COCATS 4) (Revision of COCATS 3). <i>Journal of the American College of Cardiology</i> , 2015, 65, 1721-1723.	1.2	67
31	Cbl-ArgBP2 complex mediates ubiquitination and degradation of c-Abl. <i>Biochemical Journal</i> , 2003, 370, 29-34.	1.7	66
32	Contemporary Role of Echocardiography for Clinical Decision Making in Patients During and After Cancer Therapy. <i>JACC: Cardiovascular Imaging</i> , 2018, 11, 1122-1131.	2.3	62
33	Direct Interaction of p21-Activated Kinase 4 with PDZ-RhoGEF, a G Protein-linked Rho Guanine Exchange Factor. <i>Journal of Biological Chemistry</i> , 2004, 279, 6182-6189.	1.6	61
34	Management of Patients With Giant Cell Myocarditis. <i>Journal of the American College of Cardiology</i> , 2021, 77, 1122-1134.	1.2	59
35	Strain Imaging in Cardio-Oncology. <i>JACC: CardioOncology</i> , 2020, 2, 677-689.	1.7	58
36	Preparing the Cardiovascular Workforce to Care for Oncology Patients. <i>Journal of the American College of Cardiology</i> , 2019, 73, 2226-2235.	1.2	56

#	ARTICLE	IF	CITATIONS
37	Upfront dexrazoxane for the reduction of anthracycline-induced cardiotoxicity in adults with preexisting cardiomyopathy and cancer: a consecutive case series. <i>Cardio-Oncology</i> , 2019, 5, 1.	0.8	54
38	Aromatase inhibitor and tamoxifen use and the risk of venous thromboembolism in breast cancer survivors. <i>Breast Cancer Research and Treatment</i> , 2019, 174, 785-794.	1.1	50
39	Trastuzumab-Induced Cardiomyopathy. <i>Cardiology Clinics</i> , 2019, 37, 407-418.	0.9	47
40	Burgeoning Cardio-Oncology Programs. <i>Journal of the American College of Cardiology</i> , 2015, 66, 1193-1197.	1.2	45
41	Management of Cardiovascular Disease in Women With Breast Cancer. <i>Circulation</i> , 2019, 139, 1110-1120.	1.6	45
42	Percutaneous coronary intervention in patients with cancer and readmissions within 90 days for acute myocardial infarction and bleeding in the USA. <i>European Heart Journal</i> , 2021, 42, 1019-1034.	1.0	45
43	Management of Cardiovascular Disease During Coronavirus Disease (COVID-19) Pandemic. <i>Trends in Cardiovascular Medicine</i> , 2020, 30, 315-325.	2.3	44
44	Cardiovascular toxicity after antiangiogenic therapy in persons older than 65 years with advanced renal cell carcinoma. <i>Cancer</i> , 2016, 122, 124-130.	2.0	43
45	Cardio-Oncology Education and Training. <i>Journal of the American College of Cardiology</i> , 2020, 76, 2267-2281.	1.2	41
46	Risk of cardiovascular adverse events from trastuzumab (Herceptin®) in elderly persons with breast cancer: a population-based study. <i>Breast Cancer Research and Treatment</i> , 2014, 144, 163-170.	1.1	37
47	Left Ventricular Dysfunction in Cancer Treatment. <i>JACC: Heart Failure</i> , 2018, 6, 87-95.	1.9	37
48	Electrocardiographic features of immune checkpoint inhibitor associated myocarditis. , 2021, 9, e002007.		36
49	Clinical Approach to Cardiovascular Toxicity of Oral Antineoplastic Agents. <i>Journal of the American College of Cardiology</i> , 2021, 77, 2693-2716.	1.2	35
50	Effect of primary percutaneous coronary intervention on in-hospital outcomes among active cancer patients presenting with ST-elevation myocardial infarction: a propensity score matching analysis. <i>European Heart Journal: Acute Cardiovascular Care</i> , 2021, 10, 829-839.	0.4	34
51	Cardiometabolic risk factors and survival after breast cancer in the Women's Health Initiative. <i>Cancer</i> , 2018, 124, 1798-1807.	2.0	33
52	Association of Cardiac Resynchronization Therapy With Change in Left Ventricular Ejection Fraction in Patients With Chemotherapy-Induced Cardiomyopathy. <i>JAMA - Journal of the American Medical Association</i> , 2019, 322, 1799.	3.8	32
53	SAFE-HEaRt: Rationale and Design of a Pilot Study Investigating Cardiac Safety of HER2 Targeted Therapy in Patients with HER2-Positive Breast Cancer and Reduced Left Ventricular Function. <i>Oncologist</i> , 2017, 22, 518-525.	1.9	31
54	Cardiometabolic risk factors and survival after cancer in the Women's Health Initiative. <i>Cancer</i> , 2021, 127, 598-608.	2.0	31

#	ARTICLE	IF	CITATIONS
55	Frequency of Takotsubo Cardiomyopathy in Adult Patients Receiving Chemotherapy (from a 5-Year) Tj ETQq1 1 0.784314 rgBTj/Overl	0.7	28
56	The Role of Angiotensinâ€Converting Enzyme Inhibitors and Î²â€Blockers in Primary Prevention of Cardiac Dysfunction in Breast Cancer Patients. Journal of the American Heart Association, 2020, 9, e015327.	1.6	26
57	Bivariate genetic association of KIAA1797 with heart rate in American Indians: the Strong Heart Family Study. Human Molecular Genetics, 2010, 19, 3662-3671.	1.4	25
58	Markers of Inflammation, Metabolic Risk Factors, and Incident Heart Failure in American Indians: The Strong Heart Study. Journal of Clinical Hypertension, 2012, 14, 13-19.	1.0	23
59	Racial differences in takotsubo cardiomyopathy outcomes in a large nationwide sample. ESC Heart Failure, 2020, 7, 1056-1063.	1.4	23
60	Optimizing Cardiovascular Health in Patients With Cancer: A Practical Review of Risk Assessment, Monitoring, and Prevention of Cancer Treatmentâ€Related Cardiovascular Toxicity. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2020, 40, 501-515.	1.8	23
61	Heart Failure in Relation to Anthracyclines and Other Chemotherapies. Methodist DeBakey Cardiovascular Journal, 2021, 15, 243.	0.5	23
62	Outcomes of COVID-19 in Patients With a History of Cancer and Comorbid Cardiovascular Disease. Journal of the National Comprehensive Cancer Network: JNCCN, 2020, , 1-10.	2.3	22
63	COCATS 4 Task Force 15: Trainingâ€Cardiovascular Research andâ€Scholarly Activity. Journal of the American College of Cardiology, 2015, 65, 1899-1906.	1.2	21
64	Cardiac function in BRCA1/2 mutation carriers with history of breast cancer treated with anthracyclines. Breast Cancer Research and Treatment, 2016, 155, 285-293.	1.1	21
65	Risks of Serious Toxicities from Intermittent versus Continuous Androgen Deprivation Therapy for Advanced Prostate Cancer: A Population Based Study. Journal of Urology, 2017, 197, 1251-1257.	0.2	20
66	Does cardiovascular phenotype explain the association between diabetes and incident heart failure? The Strong Heart Study. Nutrition, Metabolism and Cardiovascular Diseases, 2013, 23, 285-291.	1.1	19
67	The association between heart failure and incident cancer in women: an analysis of the Women's Health Initiative. European Journal of Heart Failure, 2021, 23, 1712-1721.	2.9	19
68	Takotsubo Cardiomyopathy Associated With Checkpoint Inhibitor Therapy. JACC: CardioOncology, 2021, 3, 330-334.	1.7	19
69	A Review of Genetics, Arterial Stiffness, and Blood Pressure in African Americans. Journal of Cardiovascular Translational Research, 2012, 5, 302-308.	1.1	18
70	Long-term follow-up assessment of cardiac safety in SAFE-HEaRt, a clinical trial evaluating the use of HER2-targeted therapies in patients with breast cancer and compromised heart function. Breast Cancer Research and Treatment, 2021, 185, 863-868.	1.1	18
71	Effects of Peroxisome Proliferator-Activated Receptor-Gamma Activation With Pioglitazone on Plasma Adipokines in Nondiabetic Patients With Either Hypercholesterolemia or Hypertension. American Journal of Cardiology, 2008, 101, 980-985.	0.7	16
72	Plasma metabolite biomarkers predictive of radiation induced cardiotoxicity. Radiotherapy and Oncology, 2020, 152, 133-145.	0.3	16

#	ARTICLE	IF	CITATIONS
73	Trends in heart disease mortality among breast cancer survivors in the US, 1975–2017. <i>Breast Cancer Research and Treatment</i> , 2022, 192, 611-622.	1.1	16
74	Lifestyle and Cardiovascular Risk Factors Associated With Heart Failure Subtypes in Postmenopausal Breast Cancer Survivors. <i>JACC: CardioOncology</i> , 2022, 4, 53-65.	1.7	16
75	Cardio-oncology Related to Heart Failure. <i>Heart Failure Clinics</i> , 2017, 13, 297-309.	1.0	13
76	Cardiovascular Care of the Oncology Patient During COVID-19: An Expert Consensus Document From the ACC Cardio-Oncology and Imaging Councils. <i>Journal of the National Cancer Institute</i> , 2021, 113, 513-522.	3.0	13
77	Usefulness of Malignancy as a Predictor of Worse In-Hospital Outcomes in Patients With Takotsubo Cardiomyopathy. <i>American Journal of Cardiology</i> , 2019, 123, 995-1001.	0.7	12
78	Team-Based Approach to Management of Hypertension Associated with Angiogenesis Inhibitors. <i>Journal of Cardiovascular Translational Research</i> , 2020, 13, 463-477.	1.1	12
79	2012 American college of cardiology foundation/society for cardiovascular angiography and interventions expert consensus document on cardiac catheterization laboratory standards update: American college of cardiology foundation task force on expert consensus documents society of thoracic surgeons society for vascular medicine. <i>Catheterization and Cardiovascular Interventions</i> , 2012, 80, 527-49.	0.7	11
80	Exercise and Aerobic Fitness to Reduce Cancer-Related Cardiovascular Toxicity. <i>Current Treatment Options in Cardiovascular Medicine</i> , 2016, 18, 44.	0.4	11
81	A Prospective Study of Early Radiation Associated Cardiac Toxicity Following Neoadjuvant Chemoradiation for Distal Esophageal Cancer. <i>Frontiers in Oncology</i> , 2020, 10, 1169.	1.3	11
82	Mechanisms of Decreased Vascular Function With Aging. <i>Hypertension</i> , 2009, 53, 900-902.	1.3	10
83	Transesophageal Echocardiographic Screening before Atrial Flutter Ablation: Is It Necessary for Patient Safety?. <i>Journal of the American Society of Echocardiography</i> , 2013, 26, 1099-1105.	1.2	10
84	Assessing cardiac safety in oncology drug development. <i>American Heart Journal</i> , 2019, 214, 125-133.	1.2	10
85	Cardio-oncological management of patients. <i>Seminars in Oncology</i> , 2019, 46, 408-413.	0.8	10
86	Breast Cancer and Heart Failure. <i>Heart Failure Clinics</i> , 2019, 15, 65-75.	1.0	10
87	Vascular Impact of Cancer Therapies: The Case of BTK (Bruton Tyrosine Kinase) Inhibitors. <i>Circulation Research</i> , 2021, 128, 1973-1987.	2.0	10
88	Lessons From Primary Cardiac Prevention Trials During Trastuzumab Therapy. <i>Journal of the American College of Cardiology</i> , 2019, 73, 2869-2871.	1.2	9
89	Long-term effectiveness of empiric cardio-protection in patients receiving cardiotoxic chemotherapies: A systematic review & bayesian network meta-analysis. <i>European Journal of Cancer</i> , 2022, 169, 82-92.	1.3	9
90	Yet Another Player in the Cardio-Oncology Conundrum?. <i>Journal of the American College of Cardiology</i> , 2014, 63, 1020-1021.	1.2	7

#	ARTICLE	IF	CITATIONS
91	Improving prediction of cardiovascular complications of cancer therapy: what does the future hold?. <i>Future Cardiology</i> , 2015, 11, 383-387.	0.5	7
92	Cardiac Protection in HER2-Targeted Treatment. <i>JAMA Oncology</i> , 2016, 2, 1037.	3.4	7
93	Optimal Treatment of Stage B Heart Failure in Cardio-Oncology?. <i>JACC: Cardiovascular Imaging</i> , 2018, 11, 1106-1108.	2.3	7
94	The landscape of cardiovascular care in pediatric cancer patients and survivors: a survey by the ACC Pediatric Cardio-Oncology Work Group. <i>Cardio-Oncology</i> , 2019, 5, 16.	0.8	7
95	Cardiovascular Prevention Strategies in Breast Cancer. <i>JACC: CardioOncology</i> , 2019, 1, 322-325.	1.7	7
96	Trends in the Use of Cardiac Imaging for Women with Newly Diagnosed Breast Cancer. <i>Journal of Cardiovascular Translational Research</i> , 2020, 13, 478-489.	1.1	7
97	Heart Failure in Relation to Tumor-Targeted Therapies and Immunotherapies. <i>Methodist DeBakey Cardiovascular Journal</i> , 2021, 15, 250.	0.5	7
98	Cardiovascular Disease Risk in Survivors of Breast Cancer. <i>Current Treatment Options in Cardiovascular Medicine</i> , 2019, 21, 79.	0.4	6
99	Cardiac Magnetic Resonance in Cardio-Oncology. <i>JACC: CardioOncology</i> , 2021, 3, 191-200.	1.7	6
100	Genetic Mutations as Risk Predictors of Atrial Fibrillation Recurrence After Catheter Ablation?. <i>Journal of the American College of Cardiology</i> , 2010, 55, 754-757.	1.2	5
101	Cardiovascular risk and communication among early stage breast cancer survivors. <i>Patient Education and Counseling</i> , 2017, 100, 1360-1366.	1.0	5
102	Left-Ventricular Function After 3 Months of Sacubitril-Valsartan in Acute Decompensated Heart Failure. <i>Journal of Cardiovascular Translational Research</i> , 2021, 14, 290-298.	1.1	5
103	Left Ventricular Assist Devices in Patients With Active Malignancies. <i>JACC: CardioOncology</i> , 2021, 3, 305-315.	1.7	5
104	Implications of cancer prior to and after heart transplantation. <i>Heart</i> , 2022, 108, 414-421.	1.2	5
105	How to Follow, Manage and Treat Cardiac Dysfunction in Patients With Her2+ Breast Cancer. <i>JACC: CardioOncology</i> , 2020, 2, 661-665.	1.7	4
106	Toward a Better Understanding of the Differential Impact of Heart Failure Phenotypes After Breast Cancer. <i>Journal of Clinical Oncology</i> , 2022, 40, 3688-3691.	0.8	4
107	Targeting Barriers of Systems of Care in a Growing Multi-disciplinary Field. <i>Current Oncology Reports</i> , 2019, 21, 36.	1.8	3
108	Cardio-Oncology and the Intersection of Cancer and Cardiotoxicity. <i>JACC: CardioOncology</i> , 2019, 1, 314-317.	1.7	3



#	ARTICLE	IF	CITATIONS
109	Prevalence and in-hospital outcomes of patients with malignancies undergoing de novo cardiac electronic device implantation in the USA. <i>Europace</i> , 2020, 22, 1083-1096.	0.7	3
110	In-Hospital Complications in Pregnant Women With Current or Historical Cancer Diagnoses. <i>Mayo Clinic Proceedings</i> , 2021, 96, 2779-2792.	1.4	3
111	Low-fat dietary pattern and long-term breast cancer incidence and mortality: The Women's Health Initiative randomized clinical trial.. <i>Journal of Clinical Oncology</i> , 2019, 37, 520-520.	0.8	3
112	Cardioprotection for Anti-HER2 Therapy: Considerations for Primary Prevention and Use in Mildly Reduced Left Ventricular Ejection Fraction. <i>Current Oncology Reports</i> , 2022, 24, 1063-1070.	1.8	3
113	Quo Vadis Trastuzumab?. <i>JACC: Heart Failure</i> , 2019, 7, 225-227.	1.9	2
114	Cardiovascular Outcomes in Relation to Antihypertensive Medication Use in Women with and Without Cancer: Results from the Women's Health Initiative. <i>Oncologist</i> , 2020, 25, 712-721.	1.9	2
115	Cardio-Oncology in 2020: Prime for Translation. <i>Journal of Cardiovascular Translational Research</i> , 2020, 13, 345-346.	1.1	2
116	Low-Fat Dietary Modification and Risk of Ductal Carcinoma In Situ of the Breast in the Women's Health Initiative Dietary Modification Trial. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2021, 30, 1753-1756.	1.1	2
117	Good News, Bad News, but Not Fake News. <i>Circulation</i> , 2017, 135, 1413-1416.	1.6	1
118	Temporal Associations and Outcomes of Breast Cancer and Heart Failure in Postmenopausal Women. <i>JACC: CardioOncology</i> , 2020, 2, 567-577.	1.7	1
119	The effect of catheter-directed thrombolytic use on readmission rates and in-hospital outcomes among cancer patients with venous thromboembolism in the United States. <i>Journal of Cardiac Surgery</i> , 2020, 35, 609-611.	0.3	1
120	From Detecting Signals to Understanding Cardiovascular Toxicities of Cancer Therapies. <i>Journal of the American College of Cardiology</i> , 2021, 78, 1814-1816.	1.2	1
121	C-reactive Protein, Fibrinogen, and Incident Heart Failure in the Strong Heart Study Population. <i>Journal of Clinical Hypertension</i> , 2013, 15, 299-299.	1.0	0
122	Heart Failure Risk Prediction in Childhood Cancer Survivors: Where Is Our Crystal Ball?. <i>Journal of Clinical Oncology</i> , 2015, 33, 379-380.	0.8	0
123	Future Clinical and Professional Directions in Cardio-oncology. , 2017, , 303-310.		0
124	P1578 Global longitudinal strain in the SAFE-HEaRT study (Cardiac SAFETY of HER2 targeted therapy in) <i>TJ ETQq0 0 0 rgBT /Overlock 10 T</i> <i>Journal</i> , 2018, 39, .	1.0	0
125	Spontaneous Coronary Artery Dissection in Levo-Transposition of the Great Arteries. <i>JACC: Case Reports</i> , 2019, 1, 146-150.	0.3	0
126	Editorial: Outcomes of Revascularization in Anti-Phospholipid Syndrome (APS): Challenges and Quests. <i>Cardiovascular Revascularization Medicine</i> , 2019, 20, 1056-1057.	0.3	0



#	ARTICLE	IF	CITATIONS
127	Clinical Presentations of Chagas Cardiomyopathy. Case Reports in Cardiology, 2020, 2020, 1-4.	0.1	0
128	Readmission after inferior vena cava filter placement for acute venous thromboembolism in the United States: Impact of a cancer diagnosis. Journal of Cardiac Surgery, 2020, 35, 2275-2278.	0.3	0
129	Recurrent Chest Pain after COVID-19: Diagnostic Utility of Cardiac Magnetic Resonance Imaging. CJC Open, 2021, , .	0.7	0
130	Cardiovascular toxicity following anti-angiogenic therapy in persons over age 65 with advanced renal cell carcinoma.. Journal of Clinical Oncology, 2015, 33, 4544-4544.	0.8	0
131	Cardio-oncology Fellowship Programs. , 2016, , 453-463.		0
132	Takotsubo and cancer. European Heart Journal, 2020, 41, 4547-4549.	1.0	0
133	Cardiovascular toxicities of chemotherapies: challenging the paradigm for left ventricular ejection fraction monitoring during and after treatment. American Heart Journal Plus, 2022, 16, 100140.	0.3	0